GTHP · Guided Therapeutics Inc
$0.21
-0.02 (-6.67%)
At close · Sep 1
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The factors below raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.72M
Shares
96.54M
GTHP metrics
57 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.21
Market cap
$21.72M
Price action
19 metricsPrice change (1W)
-16.0%
Price change (30D)
-27.6%
Price change (3M)
-7.9%
Price change (6M)
-40.0%
Price change (YTD)
-61.1%
Price change (1Y)
-25.0%
Trailing year
Price change (5Y)
-60.4%
52-week high
$0.54
52-week low
$0.16
Change from 52-week high
-61.1%
Change from 52-week low
+31.3%
Annualized volatility
186.9%
Beta
-1.9
RSI (14D)
38.5
Price vs SMA 50
-17.3%
Price vs SMA 200
-24.6%
Avg volume (3M)
10,782
Relative volume
0.9
Average dollar volume
$2,934
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
96.54M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
33.4×
reciprocal yield 3.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-14.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
191.3×
reciprocal yield 0.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
75.7%
Operating margin
-303.8%
Trailing 12 months
Net margin
-471.2%
Gross profit (TTM)
$492,000
Operating profit (TTM)
−$1.98M
Net income (TTM)
−$3.06M
Trailing 12 months
Diluted EPS (TTM)
$-0.04
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$650,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+22.4%
Year over year · more shares
Revenue CAGR (3Y)
+289.3%
Revenue CAGR (5Y)
+49.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-256.3%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$1.05M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-3.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$12,000
Total assets
$1.20M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$1.50M
Capital expenditures (TTM)
$0
R&D (TTM)
$341,000
SG&A (TTM)
—
Stock compensation (TTM)
$126,000
R&D / revenue
52.5%
Stock compensation / revenue
19.4%
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
27 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged